Lodestone Wealth Management LLC Sells 56 Shares of Eli Lilly and Company (NYSE:LLY)

Lodestone Wealth Management LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 11.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 425 shares of the company’s stock after selling 56 shares during the period. Lodestone Wealth Management LLC’s holdings in Eli Lilly and Company were worth $376,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. GFS Advisors LLC grew its stake in shares of Eli Lilly and Company by 158.8% in the 3rd quarter. GFS Advisors LLC now owns 647 shares of the company’s stock worth $573,000 after buying an additional 397 shares during the last quarter. Fort Pitt Capital Group LLC boosted its holdings in Eli Lilly and Company by 6.1% in the third quarter. Fort Pitt Capital Group LLC now owns 1,387 shares of the company’s stock worth $1,229,000 after acquiring an additional 80 shares in the last quarter. Latitude Advisors LLC grew its stake in shares of Eli Lilly and Company by 2.6% in the third quarter. Latitude Advisors LLC now owns 1,297 shares of the company’s stock worth $1,149,000 after acquiring an additional 33 shares during the last quarter. Confluence Wealth Services Inc. increased its holdings in shares of Eli Lilly and Company by 1.4% during the third quarter. Confluence Wealth Services Inc. now owns 7,129 shares of the company’s stock valued at $6,316,000 after acquiring an additional 100 shares in the last quarter. Finally, Baxter Bros Inc. increased its holdings in shares of Eli Lilly and Company by 1.0% during the third quarter. Baxter Bros Inc. now owns 1,978 shares of the company’s stock valued at $1,752,000 after acquiring an additional 20 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Barclays cut their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday. Finally, Morgan Stanley restated an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,009.00.

Eli Lilly and Company Stock Performance

LLY opened at $818.93 on Friday. The company’s 50 day moving average is $911.04 and its 200 day moving average is $866.16. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 2.03. The company has a market cap of $777.43 billion, a price-to-earnings ratio of 88.53, a PEG ratio of 3.13 and a beta of 0.43. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company’s revenue was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 13.23 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.